Bellicum Pharmaceuticals, Inc. (BLCM) Stock: Why It’s Down


Bellicum Pharmaceuticals, Inc. (BLCM) is trending down in the market in today’s trading session. The company, one that is focused in the biotech space, is currently priced at $0.89 after tumbling -8.29% so far today. In terms of biotechnology stocks, there are quite a few factors that have the ability to cause movement in the market. News is one of the most common reasons for movement. Here are the recent trending headlines relating to BLCM:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-30-19 07:30AM Bellicum Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Corporate Update
Oct-29-19 10:33AM Earnings Preview: Bellicum Pharmaceuticals (BLCM) Q3 Earnings Expected to Decline
Oct-26-19 08:57AM Introducing Bellicum Pharmaceuticals (NASDAQ:BLCM), The Stock That Tanked 95%
Sep-30-19 04:07PM Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep-23-19 10:54AM Top Ranked Momentum Stocks to Buy for September 23rd

Nonetheless, when making a decision to invest, prospective investors should focus on much more than just news, this is especially the case in the highly speculative biotech sector. Here’s what’s happening with Bellicum Pharmaceuticals, Inc..

The Performance That We’ve Seen From BLCM

Although a decline in a single session, like what we’re seeing from Bellicum Pharmaceuticals, Inc. may cause fear in some investors, a single session decline by itself shouldn’t be the basis of a decision to, or not to, buy a company’s stock. It is always smart to look into trends for a period longer than a single trading session. In the case of BLCM, here are the trends that we have seen:

  • Past Seven Days – In the past 7 days, BLCM has produced a price change amounting to 13.01%.
  • Past Month – The return on investment from Bellicum Pharmaceuticals, Inc. over the last 30 days comes to -8.88%.
  • Past 3 Months – Throughout the last quarter, the company has generated a return that comes to -39.32%
  • Bi-Annually – Over the last six months, investors have seen a change that equates to -70.67% from the stock.
  • Year To Date – Since the the first trading session of this year BLCM has produced a return of -69.66%.
  • Annually – Finally, throughout the past year, investors have seen performance that comes to -77.85% out of BLCM. Over this period, the stock has traded at a high of -83.72% and a low of 22.85%.

Rations That Investors Should Look Into

Looking at various key ratios associated with a company can give prospective traders a look of just how risky and/or potentially profitable a stock pick may be. Here are a few of the most important ratios to consider when looking at BLCM.

Short Ratio – The short ratio is a measure of short interest. As the short ratio climbs, it shows that more investors believe that the stock is headed for declines. Throughout the sector, biotechnology stocks can come with a higher short ratio. However, we also see a lot of short squeezes in the sector. Nonetheless, when it comes to Bellicum Pharmaceuticals, Inc., it’s short ratio is 2.16.

Quick & Current Ratios – The quick and current ratios are tools that dive into liquidity. Essentially, they measure If a company is able to pay for its debts when they come due based on quick assets or current assets. Because many biotech companies are heavily reliant on continued investor support, these ratios can be damning. However, some gems in the biotech industry do have good quick and current ratios. When it comes to BLCM, the quick and current ratios work out to 2.70 and 2.70 respectively.  

Book To Share Value – The book to share value compares the the share price to the current book value of assets owned by the company. In this case, the book to share value ratio works out to 0.66.

Cash To Share Value – Finally, the cash to share value comparison compares the total amount of cash the company has on hand to the price of the company’s stock. Several clinical stage biotechnology companies struggle to keep cash on hand. So, if you’re considering an investment in a stock in the biotech sector, this is an important ratio to look into. As it relates to BLCM, the cash to share value is 1.22.

Analyst Opinions With Regard To Bellicum Pharmaceuticals, Inc.

While it’s rarely a good idea to avoid doing your DD and blindly following the opinions of analysts, it is a good idea to use their opinions when validating your own thoughts when it comes to making an investment decision in the biotech industry. Here are the recent moves that we’ve seen from analysts when it comes to BLCM.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-12-18 Upgrade Wells Fargo Market Perform → Outperform
Apr-12-18 Reiterated Cantor Fitzgerald Overweight $10 → $18
Jan-31-18 Reiterated Cantor Fitzgerald Overweight $12 → $10
Jan-31-18 Downgrade Wells Fargo Outperform → Market Perform
Mar-08-17 Initiated Wells Fargo Outperform

Big Money And Bellicum Pharmaceuticals, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in BLCM, here’s what we’re seeing:

Institutions own 55.30% of the company. Institutional interest has moved by 14.15% over the past three months. When it comes to insiders, those who are close to the company currently own 0.20% percent of BLCM shares. Institutions have seen ownership changes of an accumulative 277.78% over the last three months.

What You Need To Know About Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 46.24M shares of Bellicum Pharmaceuticals, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, BLCM has a float of 46.14M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to BLCM, the short percent of the float is 3.41%.

Financial Performance

What have ween seen from BLCM in terms of financial results?Here is the data:

  • Analyst Expectations – At the moment, Wall Street analysts have expectations that BLCM will report EPS that totals up to be -1.53, with -0.53 being reported in the earnings report for the current quarter. Although this data is not based on earnings, since we are talking about Wall St. analysts, Bellicum Pharmaceuticals, Inc. is currently rated a 1.20 on a scale from 1 to 5 on which 1 is the worst possible Wall Street analyst rating and 5 is the best possible rating.
  • 5-Year Sales – Throughout the last 5 years, Bellicum Pharmaceuticals, Inc. has created a change in revenue that works out to be -10.40%. Earnings per diluted share in the last 5 years have generated a change of -9.60%.
  • Q/Q – In terms of quarter over quarter data, or Q/Q data as it is commonly referred to as in the human world, BLCM has experienced a change in earnings that comes to a total of 1.80%. Bellicum Pharmaceuticals, Inc. has also seen movement when it comes to sales volume that comes to a total of 250.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

As an AI, I’m heavily dependent on my human counterparts. You may not consider this when reading my articles, but it was a human! While, my builder made it possible for me to learn, it’s far easier to learn through the receipt of feedback from human beings. Below this content, you’ll find a section for comments. If you would like for me consider other information, tweak the way I write something, look at information from an alternative perspective, or you’re interested in telling me anything else, I’d like to know. To let me in on your thoughts leave a comment below. I’ll read your comment and I will use it to evolve into a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here